このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

青年および若年成人脳腫瘍の生存者におけるがん関連の認知障害と腸内微生物叢を改善するための仮想在宅運動介入(上昇)

2026年11月4日 更新者:Jinbing Bai、Emory University

思春期および若年成人の脳腫瘍生存者における認知障害および腸内微生物叢に関する事実上提供された在宅運動介入:パイロット無作為化対照試験

This clinical trial evaluates the impact of a research intervention of virtually supervised exercise program (RISE) on cancer-related cognitive impairment (CRCI), physical activity in adolescent and young adult (AYA) brain tumor survivors. This clinical trial also evaluates the impact of RISE on the collection of microorganisms that exist in the intestines (gut microbiome). Up to 45% of AYA brain tumor survivors experience CRCI, including issues with attention and memory. CRCI can have a negative impact on education, independent living and can worsen long-term quality of life. Moderate-intensity levels of exercise, particularly aerobic and resistance training, have been shown to improve cognitive function. Additionally, exercise can change the composition and function of the gut microbiome, which may lead to improved cognitive function. Unfortunately, only about 50% of AYAs with cancer receive exercise information or meet the physical activity recommendations. Tailoring a virtually delivered exercise intervention to meet the unique needs of AYAs may improve access to exercise. Participating in the virtual home-based exercise intervention, RISE, may improve physical activity and cognitive impairment in AYA brain tumor survivors and may also help researchers understand the relationship of exercise on the gut microbiome and cognitive function.

調査の概要

詳細な説明

PRIMARY OBJECTIVES:

I. Evaluate the feasibility of conducting a two-site pilot randomized controlled trial (RCT) to test the RISE in AYA brain tumor survivors.

II. Examine the impact of RISE on CRCI (primary) and physical activity (secondary).

EXPLORATORY OBJECTIVE:

I. Explore the impact of RISE on the gut microbiome diversity and composition.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM I (RISE INTERVENTION): Patients receive access to Physitrack and participate in personalized, progressive aerobic training over 30-40 minutes 3-5 days a week and strength training exercises 2 days a week for 12 weeks. Patients also receive active lifestyle behavior coaching over 10 minutes on 2 days a week for weeks 1-4 and then once weekly for weeks 5-12.

ARM II (ATTENTION CONTROL): Patients receive calls from the trainer once weekly for 12 weeks. Patients also wear a Fitbit for 7 days at baseline to week 12.

After completion of study intervention, patients are followed up at week 18.

研究の種類

介入

入学 (推定)

60

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

    • Georgia
      • Atlanta、Georgia、アメリカ、30322
        • 募集
        • Emory University Hospital
        • コンタクト:
        • 主任研究者:
          • Jinbing Bai, PhD, RN
    • Texas
      • Houston、Texas、アメリカ、77030
        • 募集
        • MD Anderson Cancer Center
        • コンタクト:
        • コンタクト:
        • 主任研究者:
          • Keri Schadler, PhD

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

15年~39年 (子、大人)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Age 15-39 years
  • With primary brain tumor with cranial radiotherapy
  • 6 months to 4 years post cranial radiotherapy
  • Functional Assessment of Cancer Therapy (FACT)-Cognitive Function score < 60 based on self-report (used among AYAs with non-neural cancer)
  • Able to provide informed consent/assent
  • Able to walk and receive clearance from a provider to participate based on the Physical Activity Readiness Questionnaire
  • Currently engaging in < 150 minutes of physical activity per week
  • Willing to use smartphone-based applications (app)

Exclusion Criteria:

  • Secondary malignancies, germline genetic syndrome, or recurrent disease requiring re-irradiation of the brain
  • Moderate to severe traumatic brain injury with brain damage beyond that expected from brain tumor and treatment
  • Developmental disorders (e.g., autism) or major psychotic illness (e.g., schizophrenia, depression) to avoid confounding impact related to these disorders

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:支持療法
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:トリプル

武器と介入

参加者グループ / アーム
介入・治療
実験的:Arm I (RISE)

Patients receive access to Physitrack and participate in personalized, progressive aerobic training over 30-40 minutes 3-5 days a week and strength training exercises 2 days a week for 12 weeks. Patients also receive active lifestyle behavior coaching over 10 minutes on 2 days a week for weeks 1-4 and then once weekly for weeks 5-12.

Ancillary studies

Participate in personalized, progressive aerobic training

他の名前:
  • 有酸素運動

Receive active lifestyle behavior coaching

他の名前:
  • 行動条件付け療法
  • 行動修正
  • 行動またはライフスタイルの変更
  • 行動療法
  • 行動介入

Receive access to Physitrack

Participating in strength training exercises

他の名前:
  • 筋力トレーニング
アクティブコンパレータ:Arm II (attention control)

Patients receive calls from the trainer once weekly for 12 weeks. Patients also wear a Fitbit for 7 days at baseline to week 12.

Ancillary studies

Receive calls from the trainer

他の名前:
  • 積極的なフォローアップ
  • 臨床徴候のフォローアップ
  • CLSFUP
  • ファローアップ
  • フォローした

Wear a Fitbit monitor

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Enrollment
時間枠:Up to 1.5 years

Feasibility will be ≥ 50% enrollment of eligible survivors. Descriptive statistics (e.g., frequency and percentage) will be used.

Up to 1.5 years
Adherence to research intervention of virtually supervised exercise program (RISE)
時間枠:Up to 12 weeks

Feasibility will be ≥ 75% adherence to RISE. Descriptive statistics (e.g., frequency and percentage) will be used.

Up to 12 weeks
Retention
時間枠:Up to 12 weeks

Feasibility will be ≥ 80% retention at end of intervention. Descriptive statistics (e.g., frequency and percentage) will be used.

Up to 12 weeks
Acceptability
時間枠:Up to 18 weeks

Will use an 11-item acceptability questionnaire. A ≥ 4 ("agree" to "strongly agree") per item equates to acceptability. Descriptive statistics (e.g., frequency and percentage) will be used.

Up to 18 weeks
Change in physical activity levels
時間枠:Baseline up to 18 weeks

Will be measured by Fitbit. Physical activity estimates considered as valid if the monitor is worn ≥ 10 hours/day on ≥ 4 days. Will use mixed-effect analysis of variance to model the correlation with timepoint and treatment group plus interaction if applicable, clustering on patient to control for repeated measures, and controlling for baseline measure and other covariates, which are considered prognostic or differ at baseline. A 95% level of statistical confidence will be assumed in all statistical testing.

Baseline up to 18 weeks
Change in cancer-related cognitive impairment
時間枠:Baseline up to 18 weeks

Will use mixed-effect analysis of variance to model the correlation with timepoint and treatment group plus interaction if applicable, clustering on patient to control for repeated measures, and controlling for baseline measure and other covariates, which are considered prognostic or differ at baseline. A 95% level of statistical confidence will be assumed in all statistical testing.

Baseline up to 18 weeks

二次結果の測定

結果測定
メジャーの説明
時間枠
Gut microbiome
時間枠:Up to 18 weeks

Fecal specimens will be collected for the gut microbiome. Will use mixed-effect analysis of variance to model the correlation with timepoint and treatment group plus interaction if applicable, clustering on patient to control for repeated measures, and controlling for baseline measure and other covariates, which are considered prognostic or differ at baseline. A 95% level of statistical confidence will be assumed in all statistical testing.

Up to 18 weeks
Physical function
時間枠:At baseline and at 12 and 18 weeks

Will use mixed-effect analysis of variance to model the correlation with timepoint and treatment group plus interaction if applicable, clustering on patient to control for repeated measures, and controlling for baseline measure and other covariates, which are considered prognostic or differ at baseline. A 95% level of statistical confidence will be assumed in all statistical testing.

At baseline and at 12 and 18 weeks
Patient Quality of Life
時間枠:At baseline and at 12 and 18 weeks

Will be assessed by Patient Reported Outcomes Measurement Information System-29 recommended. Will use mixed-effect analysis of variance to model the correlation with timepoint and treatment group plus interaction if applicable, clustering on patient to control for repeated measures, and controlling for baseline measure and other covariates, which are considered prognostic or differ at baseline. A 95% level of statistical confidence will be assumed in all statistical testing.

At baseline and at 12 and 18 weeks

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Jinbing Bai, PhD, RN、Emory University

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2025年2月13日

一次修了 (推定)

2027年7月31日

研究の完了 (推定)

2028年7月31日

試験登録日

最初に提出

2025年1月23日

QC基準を満たした最初の提出物

2025年1月23日

最初の投稿 (実際)

2025年1月29日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月6日

QC基準を満たした最後の更新が送信されました

2026年11月4日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する